[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP034436A - Sales de valsartan - Google Patents

Sales de valsartan

Info

Publication number
ECSP034436A
ECSP034436A EC2003004436A ECSP034436A ECSP034436A EC SP034436 A ECSP034436 A EC SP034436A EC 2003004436 A EC2003004436 A EC 2003004436A EC SP034436 A ECSP034436 A EC SP034436A EC SP034436 A ECSP034436 A EC SP034436A
Authority
EC
Ecuador
Prior art keywords
valsartan
salts
crystalline
salt
pharmaceutical preparations
Prior art date
Application number
EC2003004436A
Other languages
English (en)
Inventor
Erwin Marti
Peter Buehlmayer
Hans Rudolf Oswald
Wolfgang Marterer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034436(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP034436A publication Critical patent/ECSP034436A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a nuevas sales de valsartan, o sales cristalinas y también parcialmente cristalinas y amorfas de valsartan, a la producción y usos respectivos, y a preparaciones farmacéuticas que contienen dicha sal.
EC2003004436A 2000-07-19 2003-01-17 Sales de valsartan ECSP034436A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115556 2000-07-19

Publications (1)

Publication Number Publication Date
ECSP034436A true ECSP034436A (es) 2003-03-10

Family

ID=8169294

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004436A ECSP034436A (es) 2000-07-19 2003-01-17 Sales de valsartan

Country Status (31)

Country Link
US (5) US20030207930A1 (es)
EP (1) EP1313714B1 (es)
JP (1) JP4102664B2 (es)
KR (1) KR100529658B1 (es)
CN (2) CN1216873C (es)
AR (2) AR032758A1 (es)
AT (1) ATE406355T1 (es)
AU (2) AU2001289672B2 (es)
BR (1) BR0112665A (es)
CA (1) CA2415962C (es)
CY (1) CY1108559T1 (es)
CZ (1) CZ303389B6 (es)
DE (1) DE60135560D1 (es)
DK (1) DK1313714T3 (es)
EC (1) ECSP034436A (es)
ES (1) ES2309090T3 (es)
HK (1) HK1055963A1 (es)
HU (1) HU229280B1 (es)
IL (2) IL153882A0 (es)
MX (1) MXPA03000525A (es)
MY (2) MY152846A (es)
NO (1) NO326504B1 (es)
NZ (1) NZ523557A (es)
PE (1) PE20020613A1 (es)
PL (1) PL205715B1 (es)
PT (1) PT1313714E (es)
RU (1) RU2275363C2 (es)
SI (1) SI1313714T1 (es)
SK (1) SK287558B6 (es)
WO (1) WO2002006253A1 (es)
ZA (1) ZA200300285B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523557A (en) 2000-07-19 2004-12-24 Novartis Ag Calcium salt of valsartan
BRPI0306907B8 (pt) * 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
WO2003089417A1 (en) * 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
BR0311292A (pt) * 2002-05-17 2005-04-26 Novartis Ag Combinação de beta-bloqueador e bloqueador de receptor de angiotensina ii para prevenção secundária de infarto do miocárdio
DE60323835D1 (de) * 2002-06-13 2008-11-13 Novartis Ag Calciumsalze von statinen aus indol
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
DE602004013405T2 (de) * 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
TR200503396T1 (tr) * 2003-03-31 2006-08-21 Hetero Drugs Limited Yeni, amorf bir formda valsartan.
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
CA2592091A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
WO2007017897A2 (en) * 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
FR2886642B1 (fr) * 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
JP2010526126A (ja) * 2007-05-07 2010-07-29 シプラ・リミテッド バルサルタンの製造方法
ES2312162T3 (es) * 2007-06-07 2009-02-16 Inke, S.A. Procedimiento para la obtencion de una sal de valsartan util para la preparacion de valsartan.
BRPI0817503B8 (pt) * 2007-10-05 2021-05-25 Sstarbio Pte Ltd derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
DK3067043T3 (da) 2007-11-06 2023-02-27 Novartis Ag Farmaceutiske sammensætninger baseret på superstrukturer af angiotensinreceptorantagonist/blokker (arb) og neutral endopeptidase (nep)-hæmmer
EP2316422A1 (en) 2007-11-12 2011-05-04 Novartis AG Liquid compositions comprising valsartan
EP2601180A1 (en) 2010-08-03 2013-06-12 Novartis AG Highly crystalline valsartan
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
EP2666773B1 (en) * 2011-01-20 2017-07-26 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105541741A (zh) * 2016-01-14 2016-05-04 青岛友诚高新技术有限公司 一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) * 2016-07-29 2016-12-21 陈欣怡 一种缬沙坦的新型固体形式
EP3508479A4 (en) * 2016-09-02 2020-02-19 Noratech Pharmaceuticals, Inc. CRYSTALLINE FORMS OF VALSARTAN DISODIUM SALT
TWI648267B (zh) * 2016-09-02 2019-01-21 諾瑞特國際藥業股份有限公司 纈沙坦二鈉鹽新晶型
MX2019004992A (es) 2016-10-28 2020-02-26 Biocon Ltd Sacubitril valsartán trisódico amorfo y proceso para su preparacion.
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
EA202090398A1 (ru) 2017-07-28 2020-05-15 Синтон Б.В. Фармацевтическая композиция, включающая сакубитрил и валсартан
EP3694493A1 (en) 2017-10-13 2020-08-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Tablet containing valsartan and sacubitril
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
WO2021111464A1 (en) * 2019-12-02 2021-06-10 Harman Finochem Limited A process for the preparation of highly pure valsartan

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499017A (en) * 1983-06-06 1985-02-12 Pfizer Inc. Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
DK0443983T3 (da) * 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
BR9507086A (pt) 1994-03-17 1997-09-16 Ciba Geigy Ag Tratamento de nefroterapia diabética com valsartan
WO1996031234A1 (en) 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
NZ523557A (en) 2000-07-19 2004-12-24 Novartis Ag Calcium salt of valsartan

Also Published As

Publication number Publication date
ZA200300285B (en) 2004-03-25
US20080293791A1 (en) 2008-11-27
CN1216873C (zh) 2005-08-31
CA2415962A1 (en) 2002-01-24
US20070149587A1 (en) 2007-06-28
JP2004504307A (ja) 2004-02-12
EP1313714B1 (en) 2008-08-27
HU229280B1 (en) 2013-10-28
DK1313714T3 (da) 2008-12-15
CA2415962C (en) 2010-07-06
AU2001289672B2 (en) 2005-12-08
JP4102664B2 (ja) 2008-06-18
SI1313714T1 (sl) 2009-02-28
PL360737A1 (en) 2004-09-20
US20140073677A1 (en) 2014-03-13
NO326504B1 (no) 2008-12-15
PE20020613A1 (es) 2002-08-07
KR100529658B1 (ko) 2005-11-21
CZ303389B6 (cs) 2012-08-29
CZ2003117A3 (cs) 2003-05-14
HK1055963A1 (en) 2004-01-30
AR032758A1 (es) 2003-11-26
DE60135560D1 (de) 2008-10-09
ATE406355T1 (de) 2008-09-15
MY152846A (en) 2014-11-28
NZ523557A (en) 2004-12-24
HUP0300731A2 (hu) 2003-09-29
NO20030232D0 (no) 2003-01-17
US20120329844A1 (en) 2012-12-27
SK287558B6 (sk) 2011-02-04
CN1680341A (zh) 2005-10-12
US9499499B2 (en) 2016-11-22
RU2275363C2 (ru) 2006-04-27
PT1313714E (pt) 2008-11-03
US20030207930A1 (en) 2003-11-06
BR0112665A (pt) 2003-06-24
WO2002006253A1 (en) 2002-01-24
CY1108559T1 (el) 2014-04-09
IL153882A0 (en) 2003-07-31
US8278339B2 (en) 2012-10-02
EP1313714A1 (en) 2003-05-28
CN100413852C (zh) 2008-08-27
KR20030015888A (ko) 2003-02-25
CN1443176A (zh) 2003-09-17
PL205715B1 (pl) 2010-05-31
HUP0300731A3 (en) 2006-05-29
NO20030232L (no) 2003-01-17
SK552003A3 (en) 2003-07-01
MXPA03000525A (es) 2003-05-14
ES2309090T3 (es) 2008-12-16
IL153882A (en) 2009-09-01
MY136446A (en) 2008-10-31
AU8967201A (en) 2002-01-30
AR069374A2 (es) 2010-01-20

Similar Documents

Publication Publication Date Title
ECSP034436A (es) Sales de valsartan
ECSP045221A (es) Sales de valsartan
HN2001000281A (es) Nuevas imidazotriazinonas sustituidas
DE60100143D1 (de) Freisetzungssystem von Cyclopropenderivaten, welches eine kleinere Wassermenge benützt
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
SV2002000356A (es) Nuevos derivados de piperazina ref. pc10770aixn/bb
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
NO20031273D0 (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
CR7576A (es) Nuevas sales de perindopril y composiciones farmaceuticas que las contienen
ES2116651T3 (es) Sal de l-carnitina y composiciones que la contienen.
AR003476A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
DK0744397T3 (da) Fluorphenylsubstituerede alkenylcarboxylsyre-guanidiner som Na+/K+-antiport-inhibitorer, deres anvendelse som lægemiddel el
BR0210912A (pt) Compostos e composições como inibidores de catepsina
BR9916887A (pt) Uso de derivados de pirimidina
BR0012291A (pt) Fenoxifluorpirimidinas
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
BR0107483A (pt) Processo para a preparação de um composto
PA8511401A1 (es) Nuevos derivados de amidas heterociclicas
BR9911969A (pt) Sal e processos para a preparação de um sal, para a preparação de acetato de n-terc-butilhidroxilamina, para o isolamento de acetato de n-terc- butilhidroxilamina, e para a purificação do acetato de n-terc- butilhidroxilamina
BR9810407A (pt) Compostos fluormetoximino
CO5021190A1 (es) Agentes terapeuticos
BR0207953A (pt) Derivados de caloporosida, processos para a sua preparação e sua aplicação
NO20030474D0 (no) Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel